The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Obinutuzumab (GA101) 1,000 mg versus 2,000 mg in patients with chronic lymphocytic leukemia (CLL): Results of the phase II GAGE (GAO4768g) trial.
Joseph M. Flynn
No relevant relationships to disclose
John C. Byrd
Research Funding - Pharmacyclics
Thomas J. Kipps
Consultant or Advisory Role - Roche; Roche (U)
Research Funding - Roche
Michael Boxer
No relevant relationships to disclose
Kathryn S. Kolibaba
Research Funding - Gilead Sciences; Pharmacyclics; Roche
Nicola Tyson
Employment or Leadership Position - Roche
Stock Ownership - Roche
Jamie H. Hirata
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Jeff Porter Sharman
Research Funding - Genentech